NANO arrives at its June 5 earnings event on a sharp divergence — up 18% over the past month, down 8% across the past week, and closing yesterday at €31.24 after a 3.7% single-day bounce. That tug-of-war between the recent run and the late pullback defines the setup.
The lending market sends an unambiguous message: this is not a crowded short. Availability has climbed back above 3,300% — meaning roughly 33 shares sit available to borrow for every one currently lent out. That is as loose as borrow conditions get. The ORTEX short score, at 33.2, sits comfortably in the lower half of its range and has drifted slightly lower over the past two weeks. There is no meaningful short pressure here, and no sign of a squeeze building. One note of curiosity: cost to borrow briefly spiked to 66% on June 1 before dropping back to 9% the following day — a single-session aberration that the data shows normalised instantly, rather than any structural tightening.
The bull case rests on the clinical narrative. Recent ORTEX notes highlight strengthening investor conviction in Nanobiotix's nanoparticle radiotherapy enhancement platform, with multiple data catalysts flagged for 2026–2027. The mean analyst price target, struck as recently as June 3, is €47.80 — a 53% premium to Thursday's close. That gap is the clearest quantitative expression of where bulls think the stock belongs if the programme delivers. On the other side, the stock carries a deeply negative P/E and negative price-to-book, reflecting a pre-profitability biotech burning cash on its pipeline. An EPS surprise rank in just the 5th percentile reinforces that the company has tended to miss expectations — a structural bear concern heading into any print. The EV/EBITDA ratio, while negative and not directly comparable, has been moving less negative over the past 30 days, suggesting some narrowing of the operational gap.
Ownership adds context. Johnson & Johnson Innovation (JJDC) holds 11.6% of shares, reported as recently as March 31 with no change — a strategic anchor rather than a trading position. Notz Stucki built an entirely new stake of nearly 2 million shares by late April, and Capital Research added 845,000 shares in the same period. Goldman Sachs also added modestly in January. Taken together, recent institutional flow has been accumulative, not distributive. The most notable insider action dates back to November 2025, when CEO Laurent Levy sold approximately 295,000 shares at €17.28 — a transaction that, at the time, represented around a fifth of his then-current holdings. That sale occurred far below today's price, and no further insider activity has been filed since.
Past reactions to Nanobiotix events have been asymmetric and sharp. The April 2026 announcement produced a one-day drop of 11.5% that extended to a five-day loss of similar magnitude, while two closely-dated events in late March each opened with gains near 6–7% before giving back most of those moves within a week. Today's print is therefore less a test of whether the pipeline is progressing — that narrative is broadly accepted — and more a test of whether the disclosure matches the 53% upside the Street has already priced into its targets.
See the live data behind this article on ORTEX.
Open NANO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
